Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 22, 2010. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in interests in American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific insider transaction rather than a financial performance report.
Material Changes and Transaction Details
The filing details a transaction involving Dr. M. M. Slaoui, a Person Discharging Managerial Responsibility, and his connected person. The connected person sold Ordinary shares to meet tax liabilities following the vesting of a Share Value Plan award.
- Transaction Date: February 22, 2010
- Price per Ordinary Share ADR: $38.26
- Shares Vested: 890
- Shares Sold: 318
- Shares Retained: 572
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific transaction disclosed.
Investor Verification Points
- Verify the total number of shares sold (318) versus shares retained (572) by the connected person of Dr. M. M. Slaoui.
- Confirm the transaction price of $38.26 per Ordinary Share ADR against market data for February 22, 2010.
- Ensure the transaction was executed to meet tax liabilities related to a Share Value Plan award as stated.